Phase 2 clinical trial planned to start in H1 2023San Diego, California, December 20, 2022 — Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, today announced that the U.S. Food and Drug Administration (“FDA”) has given... Read more